<p>Join the Substack here: onthepen.substack.com<br />
Get all my links here: https://linktr.ee/manonthemounjaro</p>

Welcome back to On The Pen: The Weekly Dose, your go-to podcast for breaking GLP-1 and obesity medicine news. In this episode, host Dave Knapp (aka Man On The Mounjaro) dives deep into the week’s biggest updates — from the Trump administration’s bold executive order to enforce Most Favored Nation pricing for drugs like Zepbound and Ozempic, to a major ruling against compounded tirzepatide that could reshape access for patients across the country.

We unpack Judge Pittman’s ruling against the Outsourcing Facilities Association, what it means for 503B pharmacies, and why telehealth companies are scrambling to pivot to 503A custom dosing. Plus, we break exclusive news on EMR provider Tebra and payment processor Stripe allegedly threatening doctors with a financial blackout for prescribing compounded GLP-1 medications.

Also in this episode: big updates on the On The Pen movement — including hitting #1 on Substack in health and wellness, and the launch of our brand new newsroom, built from the ground up to keep fighting for patient access and accountability in obesity medicine.

If you care about access to Ozempic, Wegovy, Mounjaro, Zepbound, compounded semaglutide, or tirzepatide... this is the episode you cannot miss.

Trump Admin Setting Price Targets for Zepbound and Ozempic, Will Pharma Go Along?